Haemostasis in Liver Disease

Textbook of Hepatology: From Basic Science to Clinical Practice, Third Edition

Volumn , Issue , 2008, Pages 1780-1797

  Caldwell, Stephen H ^a   Northup, Patrick G ^a   Sundaram, Vinay ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Coexisting renal failure; Endothelial dysfunction; Haemostatic agents; Liver disease management; Partial thromboplastin time

Indexed keywords

EID: 84889485899     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470691861.ch21d     Document Type: Chapter

References (145)

1. Rapaport SI, Rao LVM (1995) The tissue factor pathway: how it has become a 'prima ballerina'. Thromb Haemost 74, 7-17.
2. Veldman A, Hoffman M, Ehrenforth S (2003) New insights into the coagulation system and implications for new therapeutic options with recombinant Factor VIIa. Curr Med Chem 10, 797-811.
3. Tholstrup T, Miller GJ, Bysted A et al. (2003) Effect of individual dietary fatty acids on postprandial activation of blood coagulation factor VII and fibrinolysis in healthy young men. Am J Clin Nutr 77, 1125-1132.
4. Rapaport SI (1989) Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xadependent inhibitory mechanism. Blood 73, 359-365.
5. Jackson CM, Esnouf MP, Lindahl TL (2003) A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy. Pathophysiol Haemost Thromb 33, 43-51.
6. Bauer K (2003) Approach to thrombosis. In: Loscalzo J, Schafer AI (eds) Thrombosis and Hemorrhage. Philadelphia: Lippincott Williams & Wilkins, pp. 334-335.
7. WHO Expert Committee on Biological Standardization (1983) 33rd Report. Technical Report Series No. 687. Geneva: World Health Organization.
8. Hirsh J, Poller L (1994) The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med 154, 282-288.
9. Wuillemin WA, Gasser KM, Zeerleder SS et al. (2002) Evaluation of a platelet function analyzer (PFA-100) in patients with a bleeding tendency. Swiss Med Wkly 132, 443-448.
10. Escolar G, Cases A, Vinas M et al. (1999) Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 84, 614-619.
11. Ewe K (1981) Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 26, 388-393.
12. Boks AL, Brommer EJ, Schalm SW et al. (1986) Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 6, 79-86.
13. Robert A, Chazouilleres O (1996) Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio. Hepatology 24, 1392-1394.
14. Kovacs MJ, Wong A, MacKinnon K et al. (1994) Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 71, 727-730.
15. Trotter JF, Brimhall B, Arjal R et al. (2004) Specific laboratory methodologies achieve higher Model for End-stage Liver Disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 10, 995-1000.
16. McBane RD, Felty CL, Hartgers ML et al. (2005) Importance of device evaluation for point-of-care prothrombin time International Normalized Ratio testing programs. Mayo Clin Proc 80, 181-186.
17. Tripodi A, Salerno F, Chantarangkul V et al. (2005) Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 41, 553-558.
18. Bosch J, Reverter JC (2005) The coagulopathy of cirrhosis: myth or reality? Hepatology 41, 434-435.
19. Peck-Radosavljevic MP, Zacherl J, Meng YG et al. (1997) Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 27, 127-131.
20. Samuel H, Nardi M, Karpatkin M et al. (1999) Differentiation of autoimmune thrombocytopenia from thrombocytopenia associated with immune complex disease: systemic lupus erythematosus, hepatitis-cirrhosis, and HIV-1 infection by platelet and serum immunological measurements. Br J Haematol 105, 1086-1091.
21. Rios R, Sangro B, Herrero I et al. (2005) The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 100, 1311-1316.
22. Hersch S, Kunelis T, Francis RV (1987) The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood 69, 1315-1319.
23. Green G, Thomson JM, Dymock IW et al. (1976) Abnormal fibrin polymerization in liver disease. Br J Haematol 34(3), 427-439.
24. Zachee P, Vermylen J, Boogaerts MA (1994) Hematologic aspects of end-stage renal failure. Ann Hematol 69(1), 33-40.
25. Rubin MH, Weston MJ, Langley MH et al. (1979) Platelet function in chronic liver disease: relationship to disease severity. Dig Dis Sci 24, 197-202.
26. Lisman T, Leebeek FWG, Mosnier LO et al. (2001) Thrombinactivatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 121, 131-139.
27. Fletcher AP, Biederman O, Moore D et al. (1964) Abnormal plasminogen-plasmin activity (fibrinolysis) in patients with hepatic cirrhosis: its cure and consequences. J Clin Invest 43, 681-695.
28. Agarwal S, Joyner KA, Swaim MW (2001) Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. Am J Gastroenterol 95, 3218-3224.
29. Bakker C, Knot E, Stibbe J et al. (1992) Disseminated intravascular coagulation in liver cirrhosis. J Hepatol 15, 330-335.
30. Zieve L (1958) Jaundice, hyperlipidemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis. Ann Intern Med 48, 471-496.
31. Chitale AA, Sterling RK, Post AB et al. (1998) Resolution of spur cell anemia with liver transplantation: a case report and review of the literature. Transplantation 65, 993-995.
32. Shattil SJ, Anaya-Galindo R, Bennett J et al. (1975) Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 55, 636-643.
33. Smeets EF, Comfurius P, Bevers EM et al. (1996) Contribution of different phospholipid classes to the prothrombin converting capacity of sonicated lipid vesicles. Thromb Res 81, 419-426.
34. El Khishen MA, Henderson JM, Millikan WJ Jr et al. (1985) Splenectomy is contraindicated for thrombocytopenia secondary to portal hypertension. Surg Gynecol Obstet 160, 233-238.
35. Astor RH (1966) Pooling of platelets in the spleen: role in the pathogenesis of 'hypersplenic' thrombocytopenia. J Clin Invest 45, 645-657.
36. Harker LA, Finch CA (1969) Thrombokinetics in man. J Clin Invest 48, 963-974.
37. Penny R, Rosenberg MC, Firkin BG (1966) The splenic platelet pool. Blood 27, 1-16.
38. Vyzantiadis T, Theodoridou S, Giouleme O et al. (2002) Serum thrombopoietin levels in thrombocytopenic patients with liver cirrhosis. Haematologica 87, 890-891.
39. Koruk M, Onuk MD, Akcay F et al. (2002) Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis and its relationship with circulating thrombocyte counts. Hepatogastroenterology 49, 1645-1648.
40. Adinolfi LE, Giordano MG, Andreana A et al. (2002) Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 113, 590-595.
41. Aref S, Mabed M, Selim T et al. (2004) Thrombopoietin (TPO) levels in hepatic patients with thrombocytopenia. Hematology 9, 351-356.
42. Freni MA, Spadaro A, Ajello A et al. (2002) Serum thrombopoietin in chronic liver disease: relation to severity of the disease and spleen size. Hepatogastroenterology 49, 1383-1385.
43. Ishikawa T, Ichida T, Sugahara S et al. (2002) Thrombopoietin receptor (c-Mpl) is constitutively expressed on platelets of patients with liver cirrhosis, and correlates with its disease progression. Hepatol Res 23, 115-121.
44. Levine R, Spivak J, Meagher R et al. (1986) Effect of ethanol on thrombopoiesis. Br J Haematol 14, 345-354.
45. Cowan D (1973) Thrombokinetic studies in alcohol related thrombocytopenia. J Lab Clin Med 81, 64-76.
46. Ordinas A, Escolar G, Cirera I et al. (1996) Existence of a plateletadhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. Hepatology 24, 1137-1142.
47. Walkowiak B, Michalak E, Borkowska E et al. (1994) Concentration of RGDS-containing degradation products in uremic plasma is correlated with progression in renal failure. Thromb Res 76, 133-144.
48. Doll DC (1982) Surface morphology of platelets in spur-cell anemia. Hum Pathol 13, 671-672.
49. Ulibarrena C, Vecino A, Cesar JM (1994) Red cell lipid abnormalities in acquired acanthocytosis are extended to platelets. Br J Haematol 87, 614-616.
50. Sundaram V, Al-Osaimi AMS, Lewis JJ et al. (2006) Severe prolongation of the INR in spur cell anemia of cirrhosis: true-true and related? Dig Dis Sci 51, 1203-1205.
51. Shattil SJ, Anaya-Galindo R, Bennett J et al. (1975) Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 55, 636-643.
52. Smeets EF, Comfurius P, Bevers EM et al. (1996) Contribution of different phospholipid classes to the prothrombin converting capacity of sonicated lipid vesicles. Thromb Res 81, 419-426.
53. Schaefer AI (2003) Acquired disorders of platelet function. In: Loscalzo J, Schafer AI (eds) Thrombosis and Hemorrhage. Philadelphia: Lippincott Wiliams & Wilkins, p. 526.
54. Kyrle PA, Stockenhuber F, Brenner B et al. (1988) Evidence for an increased generation of prostacyclin in the microvasculature and an impairment of the platelet alpha-granule release in chronic renal failure. Thromb Haemost 60, 205-208.
55. Mannhalter CH, Deutsch E, Kopsa E (1985) Clotting activities and antigen concentrations of contact factors in kidney disease. Thromb Res 39, 475-484.
56. Craxi A, Camma C, Giunta M (2000) Clinical aspects of bleeding complications in cirrhotic patients. Blood Coagul Fibrinolysis 11(Suppl.), S75-S79.
57. Kamath PS, Wiesner RH, Malinchoc M et al. (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33, 464-470.
58. Merion RM, Wolfe RA, Dykstra DM et al. (2003) Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl 9, 12-18.
59. Malinchoc M, Kamath PS, Gordon FD et al. (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts (comment). Hepatology 31, 864-871.
60. Rice HE, O'Keefe GE, Helton WS et al. (1997) Morbid prognostic features in patients with chronic liver failure undergoing nonhepatic surgery. Arch Surg 132, 880-884.
61. del Olmo JA, Flor-Lorente B, Flor-Civera B et al. (2003) Risk factors for nonhepatic surgery in patients with cirrhosis. World J Surg 27, 647-652.
62. Northup PG, Wanamaker RC, Lee VD et al. (2005) Model for End Stage Liver Disease (MELD) predicts non-transplant surgical mortality in patients with cirrhosis. Ann Surg 242, 244-251.
63. Sue M, Caldwell SH, Dickson RC et al. (1996) Variation between centres in technique and guidelines for liver biopsy. Liver 16, 267-270.
64. Grabau CM, Crago SF, Hoff LK et al. (2004) Performance standards for therapeutic abdominal paracentesis. Hepatology 40, 484-488.
65. Terjung B, Lemnitzer I, Dumoulin FL et al. (2003) Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 67, 138-145.
66. Furie B, Furie BC (1990) Molecular basis for vitamin K-dependent-γ-carboxylation. Blood 75, 1753-1762.
67. Furie B, Bouchard BA, Furie BC (1999) Vitamin K-dependent biosynthesis of γ-carboxyglutamic acid. Blood 93, 1798-1808.
68. Wilkins K, DeKoven J, Assaad D (2000) Cutaneous reactions associated with vitamin K1. J Cutan Med Surg 4, 164-168.
69. Chung JY, Ramos-Caro FA, Beers B et al. (1999) Hypersensitivity reactions to parenteral vitamin K. Cutis 63, 33-34.
70. Riegert-Johnson DL, Volcheck GW (2002) The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol 89, 400-406.
71. Wjasow C, McNamara R (2003) Anaphylaxis after low dose intravenous vitamin K. J Emerg Med 24, 169-172.
72. Dzik S (1999) The use of blood components prior to invasive procedures: a critical appraisal. In: Mintz PD (ed.) Transfusion Therapy: Clinical Principles and Practice. Bethesda, MD: AABB Press.
73. Bishop JF, McGrath K, Wolf MM et al. (1988) Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 71, 383-387.
74. Federowicz I, Barrett BB, Andersen JW et al. (1996) Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage. Transfusion 36, 21-28.
75. Youssef WI, Salazar F, Dasarathy S et al. (2003) Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 98, 1391-1394.
76. Kleinman S, Caulfield T, Chan P et al. (2004) Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 44, 1774-1789.
77. Keeling DM, Luddington R, Allain JP et al. (1997) Cryoprecipitate prepared from plasma virally inactivated by the solvent detergent method. Br J Haematol 96, 194-197.
78. Evatt BL, Austin H, Leon G et al. (1999) Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate. Haemophilia 5, 295-300.
79. Caldwell SH, Chang C, Macik BG (2004) Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break with tradition in need of controlled trials. Hepatology 39, 592-598.
80. Porte RJ, Caldwell SH (2005) The role of recombinant factor VII in liver transplantation. Liver Transpl 11, 872-874.
81. Hedner U (2000) Recombinant coagulation factor VIIa: from concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost 26, 363-366.
82. Hendriks HG, Meijer K, de Wolf J et al. (2002) Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis 13, 309-313.
83. Lisman T, Leebeek FW, Meijer K et al. (2002) Recombinant Factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology 35, 616-621.
84. Bernstein DE, Jeffers L, Erhardtsen E et al. (1997) Recombinant Factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 113, 1930-1937.
85. Kjalke M, Ezban M, Monroe DM et al. (2001) High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 114, 114-120.
86. Jeffers L, Chalasani N, Balart L et al. (2002) Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 123, 118-126.
87. Shami V, Caldwell S, Hespenheide E et al. (2003) Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 9, 138-143.
88. Chuansumrit A, Treepongkaruna S, Phuaradit P (2001) Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases. Thromb Haemost 85(4), 748-779.
89. Quan DJ, Bass NM, Hirose R (2003) The effect of recombinant factor VIIa and fresh frozen plasma on the INR in patients with acute and chronic liver failure. Hepatology 38, 550A.
90. Bosch J, Thabut D, Bendtsen F et al. (2004) Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized double blind trial. Gastroenterology 127, 1123-1130.
91. Levi M, Peters M, Buller HR (2005) Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 33, 883-890.
92. Sindet PS (1987) Distribution of tranexamic acid to plasma and saliva after oral administration and mouth rinsing: a pharmacokinetic study. J Clin Pharmacol 27, 1005-1008.
93. Walsh PN, Rizza CR, Matthews JM et al. (1971) Epsilon aminocaproic acid therapy for dental extractions in hemophilia and Christmas disease: a double-blind controlled trial. Br J Haematol 20, 463-475.
94. Porte RJ (2004) Antifibrinolytics in liver transplantation: they are effective, but what about the risk-benefit ratio? Liver Transpl 10(2), 285-288.
95. Manjunath G, Fozailoff A, Mitcheson D et al. (2002) Epsilonaminocaproic acid and renal complications: case report and review of the literature. Clin Nephrol 58, 63-67.
96. Eberle B, Mayer E, Hafner G et al. (1998) High-dose epsilonaminocaproic acid versus aprotinin: antifibrinolytic efficacy in firsttime coronary operations. Ann Thorac Surg 65, 667-673.
97. McSorley MW, Taraporewalla KJ (1991) Does prophylactic epsilonaminocaproic acid improve blood loss and coagulation in liver transplantation? Transplant Proc 23, 1941.
98. Scudamore CH, Randall TE, Jewesson PJ et al. (1995) Aprotinin reduces the need for blood products during liver transplantation. Am J Surg 169, 546-549.
99. Dalmau A, Sabate A, Acosta F et al. (2000) Tranexamic acid reduces red cell transfusion better than ε-aminocaproic acid or placebo in liver transplantation. Anesth Analg 91, 29-34.
100. Boylan JF, Klinck JR, Sandler AN et al. (1996) Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 85, 1043-1048.
101. Kasper M, Ramsay MAE, Nguyen AT et al. (1997) Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation. Anesth Analg 85, 281-285.
102. Porte RJ, Molenaar IQ, Begliomini B et al. (2000) Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomized double-blind study. Lancet 355, 1303-1309.
103. Findlay JY, Rettke SR, Ereth MH et al. (2001) Aprotinin reduces red blood cell transfusion: a prospective, randomized, double-blind study. Liver Transpl 9, 802-807.
104. Dalmau A, Sabate A, Koo M et al. (2004) The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study. Liver Transpl 10, 279-284.
105. Agnelli G, Berrettini M, De Cunto M et al. (1983) Desmopressininduced improvement of abnormal coagulation in chronic liver disease. Lancet 1, 645.
106. Cattaneo M, Tenconi PM, Alberca I et al. (1990) Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost 64, 358-360.
107. Lopez P, Otaso JC, Alvarez D et al. (1997) Hemostatic and hemodynamic effects of vasopressin analogue DDAVP in patients with cirrhosis. Acta Gastroenterol Latinoam 27, 59-62.
108. Agnelli G, Parise P, Levi M et al. (1995) Effects of desmopressin on hemostasis in patients with liver cirrhosis. Haemostasis 25, 241-247.
109. de Franchis R, Arcidiacono PG, Carpinelli L et al. (1993) Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club. Hepatology 18, 1102-1107.
110. Wong AY, Irwin MG, Hui TW et al. (2003) Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. Can J Anaesth 50, 14-20.
111. Hajjer KA (2003) The endothelium in thrombosis and hemorrhage. In: Loscalzo J, Schafer AI (eds) Thrombosis and Hemorrhage, 3rd edn. Philadelphia: Lippincott, pp. 206-219.
112. Remuzzi G, Livio M, Marchiaro G et al. (1978) Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by hemodialysis. Nephron 22, 347-353.
113. Zachee P, Vermylen J, Boogaerts MA (1994) Hematologic aspects of end-stage renal failure. Ann Hematol 69, 33-40.
114. Schafer AI (2003) Acquired disorders of platelet dysfunction. In: Loscalzo J, Schafer AI (eds) Thrombosis and Hemorrhage. Philadelphia: Lippincott Wiliams & Wilkins, p. 528.
115. Himmelfarb J, Holbrook D, McMonagle E et al. (1997) Increased reticulated platelets in dialysis patients. Kidney Int 51, 834-839.
116. Kim SB, Chi HS, Park JS et al. (1999) Effect of increasing serum albumin on plasma D-dimer, von Willebrand factor, and platelet aggregation in CAPD patients. Am J Kidney Dis 33, 312-317.
117. Malyszko J, Malyszko JS, Mysliwiec M (2001) Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis. Perit Dial Int 21, 158-165.
118. Kojima K, Imazu H, Matsumura M et al. (2005) Sclerotherapy for gastric fundal variceal bleeding: Is complete obliteration possible without cyanoacrylate? J Gastroenterol Hepatol 20, 1701-1706.
119. Northup PG, Caldwell SH (2005) Treatment of gastric varices. J Gastroenterol Hepatol 20, 1631-1633.
120. Detry O, Honore P, Delwaide J et al. (1999) Liver transplantation in a Jehovah's witness. Lancet 353, 1680.
121. Bruno CM, Neri S, Sciacca C et al. (2004) Plasma erythropoietin levels in anaemic and non-anaemic patients with chronic liver diseases. World J Gastroenterol 10, 1353-1356.
122. Mady E, Wissa G, Khalifa A et al. (1999) Assessment of erythropoietin levels and some iron indices in chronic renal failure and liver cirrhosis patients. Dis Markers 15, 229-236.
123. Homoncik M, Jilma-Stohlawetz P, Schmid M et al. (2004) Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 20, 437-443.
124. Cohen J, Edelman RR, Chopra S (1992) Portal vein thrombosis: a review. Am J Med 92, 173-182.
125. Oka K, Tanaka K (1979) Intravascular coagulation in autopsy cases with liver diseases. Thromb Haemost 42, 564-570.
126. Amitrano L, Guardascione MA, Brancaccio V et al. (2004) Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 40, 736-741.
127. Romero Gomez M, Suarez Garcia E, Lopez Lacomba D et al. (2000) Antiphospholipid antibodies are related to portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 31, 237-240.
128. Sacerdoti D, Merkel C, Bolognesi M et al. (1995) Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: relationships with portal hemodynamics. Gastroenterology 108, 1152-1158.
129. Wanless IR, Wong F, Blendis LM et al. (1995) Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 21, 1238-1247.
130. Anstee QM, Wright M, Goldin R et al. (2004) The Factor V Leiden mutation accelerates disease progression in a mouse model of hepatic fibrosis induced by chronic carbon tetrachloride exposure. Hepatology 40, 534A.
131. Budhiraja R, Hassoun PM (2003) Portopulmonary hypertension. Chest 123, 562-576.
132. Edwards BS, Weir EK, Edwards WD et al. (1987) Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 10, 1233-1238.
133. Welsh CH, Hassell KL, Badesch DB et al. (1996) Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 110, 710-717.
134. Carr ME Jr, Eich DM (1988) Deep venous thrombosis with coagulopathy of liver disease. VA Med 115, 76-77.
135. Espiritu JD (2000) Pulmonary embolism in a patient with coagulopathy from end-stage liver disease. Chest 117, 924-925.
136. Northup PG, Volk-Bednarz A, Berg CL (2003) Predictors of peripheral venous thromboembolism in cirrhosis. Am J Gastroenterol 98, S97 (Abstract).
137. Eisen GM, Baron TH, Dominitz JA et al. (2002) Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc 55, 775-779.
138. Ejlersen E, Melsen T, Ingerslev J et al. (2001) Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 36, 1081-1085.
139. Anantharaju A, Mehta K, Mindikoglu AL et al. (2003) Use of activated recombinant human factor VII (rhFVIIa) for colonic polypectomies in patients with cirrhosis and coagulopathy. Dig Dis Sci 48, 1414-1424.
140. Kositchaiwat C, Chuansumrit A (2001) Experiences with recombinant factor VIIa for the prevention of bleeding in patients with chronic liver disease undergoing percutaneous liver biopsies and endoscopic retrograde cholangiopancreatography (ERCP). Thromb Haemost 86, 1125-1126.
141. Castellote J, Xiol X, Cortes-Beut R et al. (2001) Complications of thoracentesis in cirrhotic patients with pleural effusion. Rev Esp Enferm Dig 93, 566-575.
142. Xiol X, Castellote J, Cortes-Beut R et al. (2001) Usefulness and complications of thoracentesis in cirrhotic patients. Am J Med 111, 67-69.
143. Berthier A-M, Guillygomarc'h A, Messner M et al. (2002) Use of recombinant factor VIIa to treat persistent bleeding following dental extractions in two cirrhotic patients. Vox Sang 82, 119-121.
144. Lucia JF, Aguilar C, Orna E et al. (2001) Successful outcome of a cirrhotic patient with postoperative haematuria treated with a single high dose of recombinant factor VIIa. Haemophilia 7, 600-602.
145. Wenker OC, Wojciechowski Z, Sheinbaum R et al. (1997) Thromboelastography. Internet J Anesthesiol 1, N3.